These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15853486)

  • 21. Early treatment.
    Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
    Goodin DS; Bates D
    Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
    Bayas A; Gold R
    J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing antibodies to interferon.
    Noronha A
    Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The treatment of multiple sclerosis with beta-interferon 1a].
    Rivera VM
    Rev Neurol; 2000 Sep 1-15; 31(5):470-1. PubMed ID: 11027100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
    Johnson KP; Due DL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R; Stürzebecher CS; Kapp JF
    Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
    [No Abstract]   [Full Text] [Related]  

  • 38. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C; Prosperini L; Sbardella E; Paolillo A
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.